Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Blood Cancer J. 2022 Jun 24;12(6):93. doi: 10.1038/s41408-022-00691-9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • DNA Methylation
  • Humans
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics

Substances

  • Antimetabolites, Antineoplastic